Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Thalidomide
Drug ID BADD_D02192
Description A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem]
Indications and Usage For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
Marketing Status Prescription
ATC Code L04AX02
DrugBank ID DB01041
KEGG ID D00754
MeSH ID D013792
PubChem ID 5426
TTD Drug ID D0U7GK
NDC Product Code 59572-205; 59572-210; 59572-220; 59572-215; 69988-0052; 63818-0424; 17337-0301; 68554-0011
Synonyms Thalidomide | Sedoval | Thalomid
Chemical Information
Molecular Formula C13H10N2O4
CAS Registry Number 50-35-1
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Deep vein thrombosisThrombomodulinP07204T0858315235749; 7878634
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eye disorder06.08.03.0010.001737%Not Available
Eye infection11.01.06.001; 06.04.05.0070.001737%
Eye pain06.08.03.002--
Eye swelling06.08.03.003--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Facial paralysis17.04.03.0080.001737%Not Available
Fatigue08.01.01.0020.059057%
Febrile neutropenia01.02.03.002; 08.05.02.0040.007527%
Feeling abnormal08.01.09.014--Not Available
Feeling jittery08.01.09.0160.001158%Not Available
Femur fracture15.08.03.003; 12.04.01.003--Not Available
Flatulence07.01.04.002--
Fluid overload14.05.06.001; 02.05.04.0040.001158%Not Available
Fluid retention20.01.02.003; 14.05.06.0020.007527%Not Available
Foot fracture15.08.03.012; 12.04.01.0120.001737%Not Available
Fracture15.08.02.001; 12.04.02.0010.005211%
Fungal infection11.03.05.001--Not Available
Fungal skin infection23.09.02.001; 11.03.05.002--Not Available
Gait disturbance17.02.05.016; 08.01.02.002--
Galactorrhoea05.03.04.002; 21.05.02.002--Not Available
Gallbladder disorder09.03.02.0010.003474%Not Available
Gastric cancer07.21.02.001; 16.13.03.0010.000302%Not Available
Gastric ulcer07.04.03.002--
Gastritis07.08.02.0010.002316%
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis11.01.07.004; 07.19.03.0010.001158%Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.022002%Not Available
Gastrointestinal infection11.01.07.012; 07.19.02.0050.001737%Not Available
Gastrointestinal pain07.01.05.005--
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 24 Pages